A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

(2013) Michinori Ogura et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

(2012) M. S. Czuczman et al.   BLOOD

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

(2011) W. G. Wierda et al.   BLOOD

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

(2011) W. G. Wierda et al.   BLOOD

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies

(2010) Bruce D. Cheson   JOURNAL OF CLINICAL ONCOLOGY

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD